ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease ...
The old adage has been around for years! Here is one of the variations: “Running will ruin your knees!” Not so, according to ...
Top 2-year-old colts from 2025 clash again in the Satsuki Sho (Japanese Two Thousand Guineas, G1T) April 19 at Nakayama ...
The writer and internet critic discusses books that reflect different facets of living in a society run by billionaires.
cleanfleetreport.co on MSN
Tata Avinya X: A bold vision for India's electric luxury future
Among dozens of futuristic machines shown at the Bharat Mobility Expo 2025, it is evident that one such concept is in the ...
The medication, suzetrigine (JOURNAVX ® ), was FDA-approved in January 2025 and became available at HSS in April 2025. It is the first non-opioid pain reliever released in more than 25 years.
Over the past five years, health systems, private equity firms and corporate giants have poured billions into the ASC market, ...
The FDA should strengthen the evidence required for the approval of drugs under its accelerated pathway and increase the ...
The AHA announced April 17 that it will present its 2026 Federal Health Care Executive Award to Cmdr. Vince Deguzman, ...
The accumulation of fat in the abdominal region, especially visceral fat (fat that accumulates between organs), significantly ...
Approval marks a major milestone in reducing gadolinium exposure while maintaining diagnostic performance, aligning with clinical guidance to use the lowest effective dose MONTREAL, April 17, 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results